(Q41972510)

14 October 2017

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab (English)

1 reference

14 October 2017

1 reference

Bernhard Berger

1

1 reference

14 October 2017

Claus Belka

series ordinal

2

1 reference

14 October 2017

28 January 2008

1 reference

14 October 2017

1 reference

14 October 2017

3

1 reference

14 October 2017

5

1 reference

Creative Commons Attribution 2.0 Generic

14 October 2017

start time

28 January 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1748-717x-3-5

0 references

cites work

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Mechanisms of cutaneous toxicities to EGFR inhibitors.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Erlotinib induced skin rash spares skin in previous radiotherapy field.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiothera

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2248588

Severe cutaneous reaction during radiation therapy with concurrent cetuximab

18 August 2018

1 reference

12 December 2020

More on severe cutaneous reaction with radiotherapy and cetuximab

1 reference

12 December 2020

Acneiform rash secondary to cetuximab plus head and neck radiotherapy

1 reference

12 December 2020

Temporal dependence of the effect of radiation on erlotinib-induced skin rash

1 reference

12 December 2020

Identifiers

DOI

10.1186/1748-717X-3-5

1 reference

Dimensions Publication ID

14 October 2017

0 references

1 reference

14 October 2017

PubMed publication ID

18226196

1 reference